Two tests and one reference [General Sta­tis­tics]

posted by ElMaestro  – Belgium?, 2020-08-31 10:23 (86 d 11:23 ago) – Posting: # 21896
Views: 2,589

Hi Brus,

» If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?
» In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).
» If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?
» Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Here's a different way to look at it:
Can the same patient(s) be affected by your two tests? If yes, it is safer to use correction. If no, no correction should be necessary.

I could be wrong, but...

Best regards,

No, of course you do not need to audit your CRO if it was inspected in 1968 by the agency of Crabongostan.

Complete thread:

 Admin contact
21,210 posts in 4,426 threads, 1,481 registered users;
online 16 (1 registered, 15 guests [including 12 identified bots]).
Forum time: Wednesday 20:46 CET (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz